It works by inhibiting an enzyme called NNMT (nicotinamide N-methyltransferase), which plays a role in slowing metabolism and increasing fat storage as we age
Retatrutide is currently in Phase 3 trials and is expected to seek regulatory approval between 2026 and 2027
Check for air bubbles
When combined with expert guidance and complementary therapies at Fusion Healthy Aging, this treatment can help you achieve sustainable, long-term results
certificate of analysis available on request Research Applications Suitable Laboratory Uses for 5-Amino-1MQ NNMT enzyme inhibition assays IC50 determination, target engagement confirmation, and 1-MNA quantification NAD+ salvage pathway modulation studies nicotinamide flux, NMN and NAD+ pool measurement SAM/SAH methyl-donor pathway and epigenetic methylation capacity research Adipocyte biology lipogenesis, adipocyte differentiation, fat mass, and lipid storage pathway studies SIRT1 and SIRT3 activation and insulin sensitivity pathway investigations Mitochondrial function and energy expenditure pathway research Skeletal muscle physiology muscle function, sarcopenia pathway, and mitophagy-related studies NNMT-overexpressing cancer cell line studies anti-proliferative and apoptotic pathway research Gut microbiome modulation research in diet-induced obesity models Cardiovascular metabolic pathway studies homocysteine, NF-B, STAT3, redox signalling Comparative NNMT inhibitor research 5-Amino-1MQ vs
Pharmacokinetic characterization in porcine models demonstrated an intravenous half-life of approximately 3 minutes, with rapid degradation via sequential amino-terminal amino acid removal and confirmed oral bioavailability
